Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2014

View Archived Issues

Phase I results for MRX-34, a first-in-class liposome formulated miR-34 mimic

Sigma-Tau describes novel HSP 90 inhibitor

Interstitial deletion of 8p23.1 indicates a new causative gene for heterotaxy

Neuregulin-1 expression correlates with sensitivity to GDC-0032 PI3K inhibitor

Researchers present a novel method to predict the risk of rejection after heart transplant

Sym-013 augments response to lung and head and neck cancer tumors

Multiple studies examine treatment of HCV infection with veruprevir/ritonavir/ombitasvir combination

Karyopharm initiates phase I trial of selinexor and decitabine in AML

Kyowa Hakko Kirin begins phase III trials of benralizumab in Japan and South Korea

Prevention of PGE2-induced bladder overactivity by TRPM8 blocker DFL-23448

LDC and Daiichi Sankyo form early drug discovery alliance

OxThera receives financing to continue key clinical programs

SOM Biotech and Vall d'Hebron Research Institute team up to develop transthyretin amyloidosis drug

Dosing begins in phase I/II trial of APR-246 in ovarian cancer

Phase III trial of Baxter's BAX-111 achieves primary endpoint

Suglat tablets launched in Japan for type 2 diabetes

Iconic Therapeutics raises funding for development of AMD therapy

Epirus Biopharmaceuticals to merge with Zalicus

New anti-CD3 antibodies disclosed by Regeneron Pharmaceuticals

Researchers at the University of Washington design novel vaccines for viral infections

Bristol-Myers Squibb presents new XIAP inhibitors for cancer

Cleveland BioLabs announces results of CBL-0102 phase I cancer trial

Chugai to launch trastuzumab emtansine in Japan

Merck KGaA synthesizes novel FAS inhibitors

Effimune reports advances in the development of a new class of monoclonal antibodies

ViiV Healthcare launches dolutegravir in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...